Partner David Rosen was quoted in a Modern Healthcare article, “Federal investigation finds holes in orphan drug approval process,” about an investigation by federal regulators that found fault with the U.S. Food and Drug Administration’s process for approving so-called orphan drugs.
While the report suggests there may be holes in the agency’s documentation process, Rosen said, that doesn’t mean that FDA reviewers aren’t weighing the impact of a drug’s regulatory or marketing history. “The fact that maybe all the i’s aren’t dotted or t’s aren’t crossed is a technical claim, but whether it has a true material bearing is another story,” he said.
While the report suggests there may be holes in the agency’s documentation process, Rosen said, that doesn’t mean that FDA reviewers aren’t weighing the impact of a drug’s regulatory or marketing history. “The fact that maybe all the i’s aren’t dotted or t’s aren’t crossed is a technical claim, but whether it has a true material bearing is another story,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”